Bloom Health Partners Inc (CSE:BLMH, OTCQB:BLMHF), a leading provider of diagnostic and health technology services, has announced a leadership transition following the departure of Andrew Morton as its chief executive officer on September 30, 2022.
Morton, who stepped down to pursue other opportunities, remains a director of the company.
In his place, the company’s chief operating officer Rosemary Elliston has been appointed to the position of Interim CEO.
READ: Bloom Health Partners opens new location in Hawaii's capital, Honolulu
Elliston, an experienced healthcare executive, brings expertise in organizational planning, team development, multimillion-dollar capital projects, and increasing visibility for growth.
"I am looking forward to working with Andrew and the rest of the Board to leverage the strong initial growth period that the company has been able to achieve and continue to transition the company into new market opportunities and further add to shareholder value," Elliston said in a statement.
"Diagnostic and health tech services is a large and rapidly growing sector and our goal is to be at the forefront of it," she added.
During his tenure at Bloom, Morton delivered strong operating results throughout fiscal 2022, positioning the company for its next phase of growth, the company said.
“The Board of Directors, Bloom staff and Ms. Elliston are committed to business continuity and a smooth transition, including ongoing communications to our shareholders and investors,” it added.
"We're excited about the next phase of growth for Bloom, as the company develops additional service offerings," Morton said. "As a director of the company, I look forward to continuing to support the team in executing on this transition."
Bloom Health Partners is a global platform for diagnostic testing, with a mission to provide innovative, customized healthcare models for businesses and their employees.
Contact the author at jon.hopkins@proactiveinvestors.com